Nita J Maihle

Title: The Innovative Contributions of Nita J. Maihle in Cancer Research

Introduction: Nita J. Maihle, an influential inventor based in New Haven, CT, has made significant contributions to the field of cancer research, highlighted by her impressive portfolio of 10 patents. Her work predominantly focuses on the discovery and application of soluble epidermal growth factor receptor isoforms, which have vital implications for cancer diagnosis and treatment.

Latest Patents: Among her groundbreaking patents, Nita has developed innovative techniques related to soluble epidermal growth factor receptor isoforms. One notable invention pertains to the identification of soluble isoforms of the Epidermal Growth Factor Receptor, or sErbB1 variants. This patented technology provides sequences of nucleic acids encoding these isoforms, along with purified recombinant proteins and novel antibodies specific for these isoforms. Moreover, it includes methods for quantifying the concentration of these protein isoforms in patient biological samples at femtomolar levels.

Another significant patent from Nita details embodiments of the p110 soluble EGFR (p110 sEGFR) peptides and nucleic acid sequences. This involves the disclosure of antibodies, detection methods, kits, and expression vectors for p110 sEGFR. The patent outlines assays on biological samples aimed at cancer risk assessment, prevention, early detection, diagnosis, prognosis, theragnosis, and monitoring of treatment responsiveness and disease progression.

Career Highlights: Nita J. Maihle's career has been marked by innovative research and substantial achievements in developing cancer-related diagnostics and therapeutics. Her ten patents underscore her expertise in discovering vital biomarkers associated with ovarian carcinoma and other cancers. Through her innovative approaches, she has paved the way for enhanced diagnostic tools and treatment modalities in oncology.

Collaborations: Nita has collaborated with esteemed colleagues such as Hakjoo Lee and Andre T. Baron, further enriching her research endeavors. These collaborations have fostered an environment of knowledge-sharing and innovation, crucial in advancing cancer research and improving patient care.

Conclusion: Nita J. Maihle’s innovative work and extensive patent portfolio reflect her commitment to furthering the understanding and treatment of cancer. Through her groundbreaking discoveries in soluble epidermal growth factor receptor isoforms, she has significantly impacted the field of oncology, providing new avenues for diagnosis and treatment that hold promise for cancer patients. Her ongoing contributions underscore the importance of innovation in the quest for effective cancer therapies.